Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIEL-ENGIC 04 biomarker-enriched anti-EGFR trial in right-sided RAS wild-type advanced colorectal cancer
2025-521209-42-00Phase 4Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of cetuximab and bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Early tumour shrinkage. Planned start Sep 2026; status: authorised.
02
Drugs
cetuximabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2025-521209-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521209-42-00.